Jkpharma Life Science Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 30-10-2024
- Paid Up Capital ₹ 0.10 M
as on 30-10-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 30-10-2024
- Revenue 3.54%
(FY 2023)
- Profit 11.88%
(FY 2023)
- Ebitda 697.81%
(FY 2023)
- Net Worth 23.10%
(FY 2023)
- Total Assets -6.41%
(FY 2023)
About Jkpharma Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.00 M.
Satyadev Yadav and Rahul Yadav serve as directors at the Company.
- CIN/LLPIN
U51397PN2020PTC196029
- Company No.
196029
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Nov 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jkpharma Life Science?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyadev Yadav  | Director | 13-Nov-2020 | Current |
| Rahul Yadav | Director | 13-Nov-2020 | Current |
Financial Performance of Jkpharma Life Science.
Jkpharma Life Science Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.54% increase. The company also saw a substantial improvement in profitability, with a 11.88% increase in profit. The company's net worth Soared by an impressive increase of 23.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jkpharma Life Science?
Unlock access to Jkpharma Life Science's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Archaic Life Science Private LimitedActive 3 years 11 monthsSatyadev Yadav and Rahul Yadav are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 15 Mar 2023 | ₹4.00 M | Open |
How Many Employees Work at Jkpharma Life Science?
Jkpharma Life Science has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jkpharma Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jkpharma Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
